Lotus Tissue Repair Lands $26,000,000 Series A Financing Round

  • Feed Type
  • Date
    6/30/2011
  • Company Name
    Lotus Tissue Repair
  • Mailing Address
    One Mifflin Place Cambridge, MA 02138
  • Company Description
    Lotus Tissue Repair is developing its proprietary recombinant human collagen Type VII (rC7) technology as a treatment for dermatologic conditions in which rC7 may play an important role in accelerating chronic wound healing, such as diabetic foot ulcers, venous stasis ulcers and similar conditions.
  • Website
    http://www.lotustissuerepair.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $26,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    Proceeds of the financing will be used to advance the company’s proprietary recombinant collagen type VII (rC7) technology as the first and only protein replacement therapy in development for the treatment of dystrophic epidermolysis bullosa (DEB), an orphan disease that causes devastating skin blisters, morbidity and early mortality
  • M&A Terms
  • Venture Investor
    Third Rock Ventures
  • Venture Investor
    Third Rock Ventures
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.